1.2 Rising awareness through education and word of mouth Historically, obesity has been viewed as a behavioral issue
Several promising innovations are on the horizon, aimed at improving patient convenience, enhancing efficacy, reducing side effects, and tailoring therapy to individual needs
These agents block the activin type II receptors (ActRIIA and ActRIIB), which are key mediators of muscle catabolism through the myostatin and activin A signaling pathways
While GLP-1 medications can be administered at any time of day (consistent with prescribing information), some patients report personal preference for evening administration
10.1016/S0140-6736(87)91194-9 62
PurpleLab, using its healthcare claims database and HealthNexus analytics platform, analyzed medical and pharmacy claims for 12.2M people taking GLP-1 medications from January 2019 May 2024